SCHEMBL7020804

SCHEMBL7020804

CCCCn1c(=O)c2[nH]c(N)nc2n(CCCC)c1=O

nearest known ligand 0.60

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 3/20 0.56
▸ ADORA2B P29275 3/20 0.56
▸ ADORA1 P30542 3/20 0.56
▸ ADORA3 P0DMS8 1/20 0.56
▸ PDE4A P27815 3/20 0.56
▸ PDE4B Q07343 3/20 0.56
▸ PDE4C Q08493 3/20 0.56
▸ PDE4D Q08499 3/20 0.56
▸ PDE5A O76074 1/20 0.56
▸ SIRT1 Q96EB6 1/20 0.55
▸ SIRT3 Q9NTG7 1/20 0.55
▸ SIRT5 Q9NXA8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7027309 0.98 ADORA2A (0.55) ADORA2AADORA2BADORA1ADORA3PDE4A
SCHEMBL10420652 0.91 SIRT1 (0.66) ADORA2BADORA1SIRT1SIRT3SIRT5
SCHEMBL7918903 0.83 ADORA1 (0.57) ADORA2AADORA2BADORA1ADORA3PDE4A
SCHEMBL7022635 0.83 SIRT1 (0.56) ADORA2AADORA2BADORA1ADORA3SIRT1
SCHEMBL3178064 0.82 SIRT1 (0.55) ADORA2AADORA2BADORA1ADORA3PDE4A
SCHEMBL7031457 0.82 SIRT1 (0.55) ADORA2AADORA2BADORA1ADORA3PDE4A
SCHEMBL10859893 0.81 SIRT1 (0.61) ADORA2AADORA1PDE4APDE4BPDE4C
SCHEMBL3119443 0.81 SIRT1 (0.54) ADORA2AADORA2BADORA1ADORA3PDE4A
SCHEMBL10856971 0.81 SIRT1 (0.61) ADORA2AADORA1PDE4APDE4BPDE4C
SCHEMBL13247926 0.79 ADORA2B (0.53) ADORA2AADORA2BADORA1ADORA3PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1120417-A2 Xanthine derivatives for the treatment of cerebrovascular disorders SMITHKLINE BEECHAM PHARMA GmbH (DE) 2001-08-01 — — EP claimed
US-5734051-A TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY BEECHAM GROUP (GB) 1998-03-31 — — US claimed
EP-0389282-A2 Xanthinederivatives, process for their preparation and their pharmaceutical use BEECHAM - WUELFING GmbH & Co. KG (DE) 1990-09-26 — — EP claimed
US-6531600-B1 8-substituted xanthines have a protective effect against the consequences of cerebral metabolic inhibition; cerebral vascular and neuronal degenerative disorders; 6-aminouracil intermediate is claimed BEECHAM GROUP P.L.C. (GB) 2003-03-11 — — US disclosed
EP-1120417-A2 Xanthine derivatives for the treatment of cerebrovascular disorders SMITHKLINE BEECHAM PHARMA GmbH (DE) 2001-08-01 — — EP disclosed
US-6180791-B1 REDUCING NITRO GROUPS TO FORM AMINO GROUPS BEECHAM GROUP P.L.C. (GB) 2001-01-30 — — US disclosed
US-5981535-A FOR TREATMENT OF ALLERGIC DISORDERS ASSOCIATED WITH ATOPY, BRONCHODILATION TO TREAT DISORDERS OF THE RESPIRATORY TRACT IN A MAMMAL SMITHKLINE BEECHAM P.L.C. (GB) 1999-11-09 — — US disclosed
US-5734051-A TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY BEECHAM GROUP (GB) 1998-03-31 — — US disclosed
EP-0389282-A2 Xanthinederivatives, process for their preparation and their pharmaceutical use BEECHAM - WUELFING GmbH & Co. KG (DE) 1990-09-26 — — EP disclosed
Send feedback